# US 11,077,314 B1 · System and method for treating patients requiring mechanical ventilation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,314 B1
- Document ID: US11077314B1
- Status: Granted
- Kind: B1
- Application number: 17/141,363
- Filed: 2021-01-05
- Granted: 2021-08-03
- Earliest claimed: 2020-04-29
- Assignees: Multi Radiance Medical
- Applicants: Multi Radiance Medical
- Inventors: Douglas Johnson; Max Kanarsky; Ernesto Leal-Junior
- Web page: https://patentgrep.com/patent/US11077314B1

## CPC

- A61N 2/002: {in combination with another treatment}
- A61N 2/004: {specially adapted for a specific therapy}
- A61N 2/06: using magnetic fields produced by permanent magnets (A61N2/12 takes precedence)
- A61N 5/0613: {Apparatus adapted for a specific treatment}
- A61N 5/067: using laser light
- A61N 2005/0629: {Sequential activation of light sources}
- A61N 2005/0644: {Handheld applicators}
- A61N 2005/0652: {Arrays of diodes}
- A61N 2005/0659: {infrared}
- A61N 2005/0662: {Visible light}
- A61N 2005/0663: {Coloured light}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Respiratory function can be preserved in patients requiring mechanical ventilation (MV), such as patients with severe COVID-19, using a photoceutical applied by a photoceutical medical device (including at least one super pulsed laser to provide superpulsed light of a first wavelength, at least two non-coherent light sources to provide light of a second wavelength, and at least two other non-coherent light sources to provide light of a third wavelength) to at least one inspiratory muscle. The photoceutical includes a combination of superpulsed light of the first wavelength, light of the second wavelength, and light of the third wavelength. At least two sites on the body of the patient can be selected and the photoceutical can be delivered: at one of the sites for a first time period; and at another of the sites for a second time period.

## Claims

### Claim 1

A method comprising:
selecting at least two sites on a body of a patient requiring mechanical ventilation for delivery of a light signal to at least one primary inspiratory muscle of the patient by a photoceutical medical device,
wherein the photoceutical medical device comprises:
at least one super pulsed laser to provide superpulsed light of a first wavelength,
at least two non-coherent light sources to provide light of a second wavelength, and
at least two other non-coherent light sources to provide light of a third wavelength,
such that the light signal comprises superpulsed light of the first wavelength, light of the second wavelength, and light of the third wavelength; and
delivering the light signal to the at least one primary inspiratory muscle of the patient by the photoceutical medical device at one of the at least two sites for a first time period from a first start time to a first end time; and
after the first end time, delivering the light signal to the at least one primary inspiratory muscle of the patient by the photoceutical medical device at another of the at least two sites for a second time period from a second start time to a second end time; and
wherein the light signal is applied to preserve a respiratory function within the body of the patient requiring mechanical ventilation while on mechanical ventilation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the at least one primary inspiratory muscle comprises at least one of a diaphragm, a sternocleidomastoid muscle, and a scalene muscle.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient suffers from severe COVID-19.

### Claim 4 (depends on 1)

The method of claim 1, wherein the photoceutical medical device comprises at least two magnetic sources to provide a magnetic signal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first wavelength is between 850 nm and 950 nm, the second wavelength is between 800 nm and 900 nm, and the third wavelength is between 580 nm and 800 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the photoceutical medical device comprises:
at least four super pulsed lasers, each configured to provide the superpulsed light of the first wavelength;
at least eight light sources, each configured to provide the light of the second wavelength;
at least eight other light sources, each configured to provide the light of the third wavelength; and
at least eight magnetic sources to provide a magnetic signal.

### Claim 7 (depends on 1)

The method of claim 1, wherein at least one of the at least two sites are on an abdomen of the patient to target a diaphragm of the patient requiring mechanical ventilation, and
wherein the delivering steps each include angling at least a portion of the photoceutical medical device so that the light signal enters the body of the patient at an angle from 10 degrees to 50 degrees to reach the diaphragm of the patient requiring mechanical ventilation.

### Claim 8 (depends on 7)

The method of claim 7, wherein the at least one of the at least two sites on the abdomen of the patient is selected so that the light signal is delivered under a ribcage of the patient requiring mechanical ventilation at a left dome or a right dome of the diaphragm of the patient.

### Claim 9 (depends on 1)

The method of claim 1, wherein the preserved respiratory function causes improved ventilation parameters, improved blood oxygenation, improved tissue oxygenation, improved immune response, decreased inflammation, minimized symptoms of post-intensive care syndrome, decreased length of intensive care unit (ICU) stay, reduced length of intubation, reduced length of mechanical ventilation, reduced acute respiratory distress syndrome, maintained muscle morphology, maintained muscle function, reduced infection, reduced inflammation, reduced sepsis, and/or decreased length of hospitalization.

### Claim 10 (depends on 1)

The method of claim 1, wherein the selecting further comprises selecting at least six sites on the body of the patient for delivery of the light signal to the at least one primary inspiratory muscle of the patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein the delivering steps are completed sequentially by placing the photoceutical medical device at an edge of costal cartilage while avoiding the xiphoid process at one or more of the at least six sites.

### Claim 12 (depends on 1)

The method of claim 1, wherein the selecting further comprises:
selecting at least six sites on an abdomen of the patient for delivery of the light signal to the patient's diaphragm; and
selecting at least two additional sites on a neck of the patient for delivery of the light signal to the patient's sternocleidomastoid and/or scalene muscles.

### Claim 13 (depends on 1)

The method of claim 1, wherein the first time period and the second time period each comprises from 30 seconds-300 seconds.

### Claim 14 (depends on 1)

The method of claim 1, wherein a dose of 31.5 J is delivered at each of the at least two locations by the photoceutical medical device.